Showing 2987 results
-
Story /Novartis chemists receive “Heroes of Chemistry” honor from the American Chemical Society for work on CML drug discovery.
-
Story /Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.
-
Press release /If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based…
-
Story /For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-…
Pagination
- ‹ Previous page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- …
- 299
- › Next page